Jose Rodriguez-Romaguera1, Benjamin D Greenberg2, Steven A Rasmussen2, Gregory J Quirk3. 1. Departments of Psychiatry and Anatomy and Neurobiology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico. 2. Department of Psychiatry and Human Behavior, Brown University, Providence, Rhode Island. 3. Departments of Psychiatry and Anatomy and Neurobiology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico. Electronic address: gregoryjquirk@gmail.com.
Abstract
BACKGROUND: Obsessive-compulsive disorder is treated with exposure with response prevention (ERP) therapy, in which patients are repeatedly exposed to compulsive triggers but prevented from expressing their compulsions. Many compulsions are an attempt to avoid perceived dangers, and the intent of ERP is to extinguish compulsions. Patients failing ERP therapy are candidates for deep brain stimulation (DBS) of the ventral capsule/ventral striatum, which facilitates patients' response to ERP therapy. An animal model of ERP would be useful for understanding the neural mechanisms of extinction in obsessive-compulsive disorder. METHODS: Using a platform-mediated signaled avoidance task, we developed a rodent model of ERP called extinction with response prevention (Ext-RP), in which avoidance-conditioned rats are given extinction trials while blocking access to the avoidance platform. Following 3 days of Ext-RP, rats were tested with the platform unblocked to evaluate persistent avoidance. We then assessed if pharmacologic inactivation of lateral orbitofrontal cortex (lOFC) or DBS of the ventral striatum reduced persistent avoidance. RESULTS: Following Ext-RP training, most rats showed reduced avoidance at test (Ext-RP success), but a subset persisted in their avoidance (Ext-RP failure). Pharmacologic inactivation of lOFC eliminated persistent avoidance, as did DBS applied to the ventral striatum during Ext-RP. CONCLUSIONS: DBS of ventral striatum has been previously shown to inhibit lOFC activity. Thus, activity in lOFC, which is known to be hyperactive in obsessive-compulsive disorder, may be responsible for impairing patients' response to ERP therapy.
BACKGROUND: Obsessive-compulsive disorder is treated with exposure with response prevention (ERP) therapy, in which patients are repeatedly exposed to compulsive triggers but prevented from expressing their compulsions. Many compulsions are an attempt to avoid perceived dangers, and the intent of ERP is to extinguish compulsions. Patients failing ERP therapy are candidates for deep brain stimulation (DBS) of the ventral capsule/ventral striatum, which facilitates patients' response to ERP therapy. An animal model of ERP would be useful for understanding the neural mechanisms of extinction in obsessive-compulsive disorder. METHODS: Using a platform-mediated signaled avoidance task, we developed a rodent model of ERP called extinction with response prevention (Ext-RP), in which avoidance-conditioned rats are given extinction trials while blocking access to the avoidance platform. Following 3 days of Ext-RP, rats were tested with the platform unblocked to evaluate persistent avoidance. We then assessed if pharmacologic inactivation of lateral orbitofrontal cortex (lOFC) or DBS of the ventral striatum reduced persistent avoidance. RESULTS: Following Ext-RP training, most rats showed reduced avoidance at test (Ext-RP success), but a subset persisted in their avoidance (Ext-RP failure). Pharmacologic inactivation of lOFC eliminated persistent avoidance, as did DBS applied to the ventral striatum during Ext-RP. CONCLUSIONS: DBS of ventral striatum has been previously shown to inhibit lOFC activity. Thus, activity in lOFC, which is known to be hyperactive in obsessive-compulsive disorder, may be responsible for impairing patients' response to ERP therapy.
Authors: Julia F Lehman; Benjamin D Greenberg; Cameron C McIntyre; Steve A Rasmussen; Suzanne N Haber Journal: J Neurosci Date: 2011-07-13 Impact factor: 6.167
Authors: Edna B Foa; Michael R Liebowitz; Michael J Kozak; Sharon Davies; Rafael Campeas; Martin E Franklin; Jonathan D Huppert; Kevin Kjernisted; Vivienne Rowan; Andrew B Schmidt; H Blair Simpson; Xin Tu Journal: Am J Psychiatry Date: 2005-01 Impact factor: 18.112
Authors: Lara Menzies; Samuel R Chamberlain; Angela R Laird; Sarah M Thelen; Barbara J Sahakian; Ed T Bullmore Journal: Neurosci Biobehav Rev Date: 2007-10-17 Impact factor: 8.989
Authors: B D Greenberg; L A Gabriels; D A Malone; A R Rezai; G M Friehs; M S Okun; N A Shapira; K D Foote; P R Cosyns; C S Kubu; P F Malloy; S P Salloway; J E Giftakis; M T Rise; A G Machado; K B Baker; P H Stypulkowski; W K Goodman; S A Rasmussen; B J Nuttin Journal: Mol Psychiatry Date: 2008-05-20 Impact factor: 15.992
Authors: Isidoor O Bergfeld; Eva Dijkstra; Ilse Graat; Pelle de Koning; Bastijn J G van den Boom; Tara Arbab; Nienke Vulink; Damiaan Denys; Ingo Willuhn; Roel J T Mocking Journal: Curr Top Behav Neurosci Date: 2021
Authors: Maria M Diehl; Karolina M Lempert; Ashley C Parr; Ian Ballard; Vaughn R Steele; David V Smith Journal: Eur J Neurosci Date: 2018-08-20 Impact factor: 3.386
Authors: Maria M Diehl; Christian Bravo-Rivera; Jose Rodriguez-Romaguera; Pablo A Pagan-Rivera; Anthony Burgos-Robles; Ciorana Roman-Ortiz; Gregory J Quirk Journal: Elife Date: 2018-05-31 Impact factor: 8.140
Authors: Freddyson J Martínez-Rivera; Marcos J Sánchez-Navarro; Carlos I Huertas-Pérez; Benjamin D Greenberg; Steven A Rasmussen; Gregory J Quirk Journal: Transl Psychiatry Date: 2020-07-03 Impact factor: 6.222